PROGLYCEM SUSPENSION Rx
Generic Name and Formulations:
Diazoxide 50mg/mL; chocolate-mint flavor; contains alcohol 7.25%.
Indications for PROGLYCEM SUSPENSION:
Management of hypoglycemia due to hyperinsulinism associated with: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy in adults; leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis in infants and children.
Adults and Children:
Individualize. Infants and newborns: Initially 10mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 8–15mg/kg divided into 2–3 equal doses every 8–12hrs. Adults and children: Initially 3mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 3–8mg/kg divided into 2–3 equal doses every 8–12hrs. Refractory hypoglycemia: may require higher dosages. Discontinue if not effective after 2–3 weeks.
Functional hypoglycemia. Thiazide hypersensitivity.
Compromised cardiac reserve: may precipitate CHF. Hyperuricemia. History of gout. Renal impairment: consider reducing dose; evaluate serum electrolyte levels. Newborns with increased bilirubinemia. Monitor for respiratory distress (esp. in those with risk factors); discontinue if pulmonary hypertension is suspected. Monitor blood glucose, BUN, creatinine clearance, hematocrit, platelets, total and differential leukocyte counts, AST, serum uric acid periodically until stabilized. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antihypertensives potentiated. Concomitant coumarin: may need to reduce dose of anticoagulant. Concomitant diphenylhydantoin may result in loss of seizure control. Concomitant thiazides, other diuretics may potentiate hyperglycemic and hyperuricemic effects. Inhibits glucagon-stimulated insulin release and causes false-negative insulin response to glucagon.
Nondiuretic benzothiadiazine derivative.
Sodium and fluid retention, diabetic ketoacidosis, hyperosmolar nonketotic coma, hirsuitism, hyperglycemia, glycosuria, GI upset, tachycardia, palpitations, increased serum uric acid, thrombocytopenia (may require discontinuation), neutropenia, rash, headache, weakness, malaise.
Susp—30mL (w. dropper)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- Higher Radiation Dose May Not Improve Prostate Cancer Outcomes
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches